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Soluble receptor for advanced glycation end 
products 
A B S T R A C T   
The soluble receptor for advanced glycation end-products (sRAGE) has been classically considered a sink for pro- 
inflammatory RAGE ligands and as such has been associated with protection from inflammatory stress and 
disease. An alternative, though not mutually exclusive view is that high levels of sRAGE in circulation reflect the 
overstimulation of cell surface RAGE which if persistent, lead to the amplification of pro-inflammatory processes 
and the exacerbation of pathological states. With these two scenarios in mind this review focuses on the potential 
role of sRAGE as a prospective biomarker of disease risk and adverse outcomes.   
1. Introduction 
The receptor for advanced glycation end-products (RAGE) and its 
soluble forms - collectively known as sRAGE - are increasingly impli-
cated in host defence from infections, inflammation, cardiometabolic 
disorders and age-related diseases [1–3]. Over the last twenty years 
hundreds of papers have described correlations between sRAGE levels 
and pathophysiological states or disease prognosis, but findings have 
been inconsistent [4,5]. 
In this paper I review briefly the biology underlying the generation of 
sRAGE isoforms and the factors that modulate their levels in the circu-
lation. Then, I discuss the potential functions of sRAGE molecules as well 
as their relationship with oxidative stress, to finally focus on the evi-
dence supporting their potential use as a biomarker of disease risk and 
adverse outcomes. 
2. RAGE signalling 
RAGE is a multiligand pattern recognition cell surface receptor 
belonging to the immunoglobulin superfamily [1]. Advanced glycation 
end-products (AGEs), which arise from the non-enzymatic glycation and 
oxidation of proteins, lipids and nucleic acids, were the first RAGE li-
gands to be described [6], giving this receptor its name. Over the years 
following its discovery, it became increasingly recognized that RAGE 
binds also a variety of other ligands, including molecules derived from 
stressed or damaged cells — e.g., amyloid β peptide, high-mobility 
group box 1 (HMGB1) and S100 proteins — collectively known as 
damage associated molecular patterns (DAMPs), cell adhesion mole-
cules — e.g. the β2 integrin MAC-1 —, and molecules originating from 
bacteria, viruses and parasites (reviewed in Refs. [1,7]). As such RAGE 
plays an important role in the innate immune response and as a mediator 
of pro-inflammatory processes. Upon ligand binding RAGE-mediated 
intracellular signalling (reviewed in Ref. [2]) can lead to an increase 
in the production of reactive oxygen species (ROS) [8–10] and to the 
sustained activation of the transcription factor NFkB [11]. The latter 
stimulates the expression of pro-inflammatory modulators (e.g., IL1- β, 
VCAM-1 and TNF-α) [12,13], and of RAGE itself [12], thus providing a 
positive feedback mechanism to amplify the inflammatory response (see 
Fig. 1). 
RAGE is constitutively expressed at high levels in the lungs and skin 
of healthy adults [14,15], whereas expression in other tissues is either 
virtually absent — e.g. in skeletal muscle [16] — or low —e.g. in cells of 
the cardiovascular, immune and central nervous systems (reviewed in 
Refs. [2,16]). However, in cardiometabolic, inflammatory or age-related 
diseases RAGE expression increases in different cell types [2,16], this 
upregulation being a direct consequence of an increase in ligand levels 
associated with these conditions [1]. Similarly, expression also increases 
in acute muscle injury [16] and during the host response to infection [3]. 
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3. The sources of soluble RAGEs and their regulation 
In addition to cell membrane-anchored RAGE, there are two major 
soluble forms of this receptor detected in blood and other body fluids, 
both of which lack its transmembrane and cytoplasmic domains [4]. 
These two RAGE isoforms are jointly known as soluble RAGE (sRAGE). 
One form of sRAGE, sometimes called cRAGE, is generated at the cell 
surface by the proteolytic cleavage of RAGE at the boundary between its 
extracellular and transmembrane portions [17,18]. This RAGE ectodo-
main shedding is stimulated by inflammatory signals, including HMGB1 
[18], lipopolysaccharide [19] and TNF-α [19]. In addition, activation of 
G protein-coupled receptors [20], intracellular calcium mobilization 
[21] and elevation of cAMP levels [22] have also been reported to 
promote this process. Two metalloproteases have been implicated in the 
generation of the cleaved form of sRAGE, MMP9 [17,19] and ADAM10 
[17–19]. MMP9 expression is known to be up-regulated by ROS and the 
activation of the RAS-ERK-NFkB pathway (reviewed in Ref. [23]). 
Furthermore, TNF-α and RAGE overexpression can also increase MMP9 
expression [19]. Similarly, TNF-α and RAGE overexpression can stimu-
late ADAM10 activation via an ATF4-dependent mechanism [19]. Taken 
together, these events are consistent with RAGE downstream signals 
promoting sRAGE shedding through an amplification mechanism 
involving auto-induction and/or induction of other inflammatory cyto-
kines (Fig. 1). 
The second form of sRAGE, called esRAGE (for endogenous secretory 
RAGE) or RAGEv1, results from alternative splicing of RAGE pre-mRNA 
[24,25] and accounts for less than 25% of total circulating sRAGE [26] 
(Fig. 1). The precise mechanism which regulates the formation of esR-
AGE is not entirely understood. The alternative splicing of RAGE 
pre-mRNA generates more than 20 splice variants, of which full length 
membrane-bound RAGE and esRAGE are the two most abundant [24]. 
The RAGE gene (AGER) has 11 exons. esRAGE is produced by inclusion 
of part of intron 9 with exon 9 and exclusion of exon 10. This results in a 
variant which has a reading frame shift at amino acid residue 332 and 
lacks the intracellular and transmembrane domains [24]. In neuro-
blastoma, human umbilical vein endothelial cells and HepG2 cells two 
splicing factors, namely heterogeneous nuclear ribonucleoprotein A1 
(hnRNP A1) and Transformer 2β-1 (Tra2β-1), have been shown to 
regulate the ratio between full length RAGE and esRAGE by exerting 
antagonistic effects on the selection of alternative exons [27]. Further-
more, in neuroblastoma cells glucose deprivation induced an up-regu-
lation of hnRNP A1 and down-regulation of Tra2β-1, resulting in a 
decrease in esRAGE expression and an in increase in the RAGE/esRAGE 
ratio [27]. These findings suggest that impaired glucose metabolism 
may be one factor affecting the regulation of esRAGE levels. 
sRAGE isoforms are highly stable [28] and can be measured from 
stored frozen serum or plasma samples using antibody-based ELISA as-
says. There are two types of assays. One assay detects total sRAGE, 
whereas the other measures specifically esRAGE. The latter uses an 
antibody directed against the unique COOH-terminal sequence of 
RAGE-v1 and does not cross-react with the cleaved form of sRAGE. 
esRAGE and sRAGE levels are strongly correlated [26,29–31] and values 
in plasma and serum are quite comparable [28]. 
Average sRAGE concentrations in different studies generally fall 
within a similar range, although there is substantial variability between 
individuals [26,30–41]. For example, in sera of 1228 European com-
munity dwelling older adults enrolled in the FRAILOMIC study, the 
median value of sRAGE was 1228 pg/ml with an interquartile range of 
943–1638 pg/ml [41]. Importantly, sRAGE levels are invariably higher 
in people with diminished kidney function [26,30,42] and in some 
studies they also tend to be higher in diabetics [33,43]. 
Part of the variability in blood levels of sRAGE is probably deter-
mined by genetic differences between individuals. AGER is a highly 
polymorphic gene [44], with some variants affecting levels of both the 
cleaved form of sRAGE and esRAGE [30]. Furthermore, sRAGE levels 
may be influenced by polymorphisms in other genes, for example in 
ADAM10 [45]. Finally, levels of both sRAGE isoforms are strongly 
affected by ethnicity, being lower in people from Afro-Caribbean and 
Hispanic origin than in Caucasians [26,30,35]. 
Other studies in patients with cardiometabolic conditions have 
shown that the concentration of sRAGE isoforms in blood can be influ-
enced by therapeutic agents, including angiotensin receptor blockers 
(ARBs), angiotensin converting enzyme inhibitors, calcium channel 
antagonists, statins and thiazolidinediones (reviewed in Ref. [4]). ARBs 
were found to decrease sRAGE levels in angiotensin II-treated endo-
thelial cells and in patients with essential hypertension [46]. Similarly, 
the calcium channel blocker azelnidipine was shown to reduce sRAGE in 
non-diabetic chronic nephropathy [47]. In contrast, statins and thiazo-
lidinediones cause an increase in blood levels of both total sRAGE and 
esRAGE in type 2 diabetes [48–50]. Likewise, physical exercise has been 
reported to increase esRAGE levels in people at low/intermediate risk of 
cardiovascular disease (CVD) [51]. The detailed mechanisms underlying 
the different effects of these interventions are not known, though in the 
case of statins, these were reported to stimulate RAGE shedding by an 
ADAM10-mediated mechanism [52]. In addition, some of the drugs may 
affect sRAGE levels by inhibiting inflammation pathways [53] or by 
improving renal function [26,42]. 
4. The function of sRAGE 
The function that sRAGE plays in human biology has been the subject 
of substantial debate. A widely held view is that sRAGE fulfills a 
Fig. 1. Mechanisms of sRAGE generation. Plasma membrane-bound RAGE 
consist of three main regions: an intracellular tail (green), a transmembrane 
helix (brown) and an extracellular domain (red) formed by the 
immunoglobulin-like subdomains V, C1 and C2. Ligand binding to the extra-
cellular domain initiates intracellular signalling, leading to the generation of 
ROS and to the activation of the transcription factor NFkB. The latter induces 
gene expression of pro-inflammatory cytokines such as TNF-α and of RAGE it-
self. RAGE downstream signalling events in turn promote the upregulation of 
MMP9 and ADAM10, which cleave membrane-bound RAGE, causing the release 
of its extracellular portion (cRAGE). ATF4 is linked to ADAM10 upregulation. 
cRAGE constitutes the majority of sRAGE. Alternative splicing of the RAGE gene 
(AGER) results in the generation of esRAGE, which also contributes to the 
sRAGE pool. A unique amino acid sequence in esRAGE (purple) distinguishes it 
from cRAGE. 
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protective anti-inflammatory role by acting as a decoy receptor, binding 
RAGE ligands and thus blocking their interaction with membrane-bound 
RAGE. In support of this possibility experiments in animals models of 
diabetes and/or CVD have shown that administration of recombinant 
sRAGE improves vascular and renal function, reduces myocardial 
ischaemic injury, as well as atherosclerosis, vascular inflammation and 
other diabetic complications (Reviewed in Ref. [1]). In addition, sRAGE 
administration has been shown to decrease inflammation in an animal 
model of multiple sclerosis [54]. In considering the function of sRAGE as 
a decoy receptor, it is relevant to note that in RAGE-deficient mice (Ager 
− /− ) sRAGE can still block certain inflammation responses, probably by 
preventing putative RAGE ligands from interacting with other receptors 
[55]. 
Aside from behaving as a decoy receptor sRAGE may also act as a 
ligand of the leukocyte integrin MAC-1 and transduce pro-inflammatory 
signals, thereby inducing leukocyte recruitment to sites of injury or 
inflammation [56,57]. Consistent with this role, bacterial burden and 
neutrophil infiltration was shown to worsen following sRAGE adminis-
tration in a mouse model of bacterial lung infection, suggesting that in 
acute settings sRAGE may actually sustain inflammation [58]. In 
contrast, sRAGE has been shown to prevent leukocyte recruitment in a 
diabetic mouse model of acute peritonitis [59]. 
sRAGE forms have been measured in humans in search for associa-
tions with disease states or their risk factors (reviewed in Refs. [60,61]). 
Many of these studies reported sRAGE levels to be lower in people with 
cardiometabolic and other chronic conditions than in healthy subjects, 
providing further support to the notion that sRAGE fulfills a protective 
role [60]. Nevertheless, positive associations between sRAGE levels and 
prevalent ill health have also been described, most notably in the con-
texts of diabetes and renal disease [60,61], and more recently also in 
frailty [62]. These contrasting lines of evidence suggest that the status of 
sRAGE in human pathophysiology deserves further examination. In this 
regard, an alternative view argues that the amount of sRAGE generated 
in vivo may not be sufficient to compete effectively with 
membrane-bound RAGE for ligand binding, particularly in situations 
where RAGE itself is also upregulated [2]. Furthermore, an increase in 
total circulating levels of sRAGE may reflect increased RAGE activation 
and autoinduction [18,63], and in this way attest to a condition of 
low-grade chronic inflammation, rather than to a healthy state. 
5. The relationship between sRAGE and oxidative stress 
Several lines of evidence indicate that RAGE activation by AGEs and 
other ligands cause oxidative stress [8,9,64,65]. Consistent with this 
notion and in keeping with the decoy receptor concept described above, 
sRAGE has been shown to reduce markers of oxidative stress when 
administered to animal models of vascular dysfunction [66,67]. Hence, 
sRAGE is sometimes attributed an ‘anti-oxidant role’. This view has been 
also supported by reports from small clinical studies of atherosclerotic 
vascular disease or cardiometabolic disorders describing inverse corre-
lations between sRAGE levels and makers of oxidative stress [68–73], 
and by a study describing a positive correlation with plasma 
anti-oxidant defenses in Alzheimer’s disease patients [74]. However, it 
should be noted that these types of associations are not universal. Thus 
for example in acute liver failure, both a protein oxidation marker and 
sRAGE levels were shown to be elevated [75], whereas in patients with 
sickle cell disease an increase in sRAGE was positively correlated with an 
increase in the levels of ferritin, which in this condition is indicative of 
iron overload [76]. In addition, in a recent study of patients with type 2 
diabetes, compared to non-diabetic controls both sRAGE levels and 
malondialdehyde were shown to be elevated, whereas antioxidant thiol 
levels were shown to be reduced [77]; furthermore, this study reported 
that these differences were even more pronounced in individuals who 
had developed diabetic retinopathy [77]. Mechanistically, a 
ROS-induced up-regulation of MMP9 [23], which in turn would result in 
an increase in RAGE ectodomain shedding, provides a reasonable 
explanation for these findings. 
Human interventional studies that examined sRAGE levels and 
markers of oxidative status, provide further insights into the relationship 
between these parameters in vivo. In master athletes a Mediterranean 
diet was shown to reduce both sRAGE and malondialdehyde [78]. 
Furthermore, in type 2 diabetes it was recently demonstrated that 
treatment with metformin for three months resulted in a reduction in 
sRAGE levels and oxidative stress markers, and also in an increase in 
antioxidant defenses [79]. Thus, taken together the above examples 
caution against considering a comparatively high level of sRAGE, a sign 
of low oxidative burden and/or good health. 
6. sRAGE as a marker of incident disease and adverse outcomes 
A variety of prospective studies have examined the relationship be-
tween sRAGE and the incidence of chronic diseases and/or the occur-
rence of adverse clinical outcomes. Table 1 summarizes examples of 
such studies in population samples of different health characteristics. 
For adults who in the main had no documented pre-existing chronic 
conditions at baseline, findings were mixed. In non-prescreened adults 
from the general population, positive [80] or no significant associations 
[40,81] were generally reported, whereas for individuals with no prior 
history of CVD, the associations with incident disease or adverse events 
were found to be negative [38,82,83]. In contrast, studies carried out in 
diabetics (type I or type 2) consistently reported that high levels of 
sRAGE were predictive of cardiovascular events and/or mortality [26, 
36,84–86]. Similarly, other studies have shown that in individuals with 
pre-existing heart failure [31,34,37,87], coronary artery disease [39, 
88], frailty [41,89] or physical disability [32], high sRAGE levels were 
associated with a higher incidence of adverse cardiovascular events 
and/or mortality. On the other hand, absence of associations with 
adverse events, have also been described, including in patients with 
advanced chronic kidney disease [90,91], in another cohort of in-
dividuals with pre-existing heart failure [92], and in a large cohort of 
people with chronic obstructive pulmonary disease and high cardio-
vascular risk [93]. Finally, a negative association between total sRAGE 
or esRAGE and mortality has been reported in cancer [29]. Taken 
together, these observational studies indicate that the relationship be-
tween total sRAGE (or esRAGE) and disease risk or the occurrence of 
adverse events, including mortality, is complex. Explanations for con-
flicting findings between different studies could be related to the de-
mographic, genetic and health characteristics of the populations under 
investigation. In particular, the presence of frailty, diabetes and 
impaired kidney function may have a strong influence on these re-
lationships [41,61]. In addition, some studies could have been statisti-
cally underpowered to detect significant prospective associations or 
might have not accounted for potentially relevant confounders (e.g., 
renal function). 
In addition to its evaluation as a prognostic biomarker in chronic 
conditions, sRAGE has also been studied in acute settings. Consistent 
with the notion that RAGE is highly overexpressed in lung epithelium 
and that RAGE signalling may play a central role in the pathological 
manifestations of lung injury, elevated sRAGE levels, were found to 
predict 90-day mortality in patients suffering from acute respiratory 
distress syndrome [94]. Similarly, elevated sRAGE levels are associated 
with looming mortality in sepsis [95] and acute liver failure [75], 
reflecting the prominent role that DAMPs play in RAGE activation in 
these conditions [3]. 
7. Concluding remarks 
Although sRAGE has been studied as a marker of disease risk and 
adverse outcomes for many years, its potential prognostic value con-
tinues to be questioned due to the inconsistency in the directionality of 
the associations observed in different clinical settings. As a telltale 
footprint left from the sustained RAGE stimulation and the concomitant 
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relentless cellular stress caused by an enduring inflammatory milieu, 
sRAGE may be a useful prognostic biomarker of irreversible loss of ho-
meostasis and eventual mortality. As such sRAGE may not be useful for 
prognosis in the general “healthy” population. Instead, its clinical 
application may be more suited to multimorbid individuals or to those 
who have been afflicted by a chronic illness for a considerable length of 
time. Thus, for example, in the cardiovascular setting, elevated sRAGE 
levels have been recently shown to be highly predictive of mortality in 
patients who were also frail [41]. Similarly, in acute conditions a dra-
matic and sustained increase in sRAGE levels may be also a sign of 
impending irreversible organ damage and mortality, for example in 
acute lung injury/acute respiratory distress syndrome [96]. Theoreti-
cally, this could be relevant in respiratory viral illnesses such as 
Covid-19, where increased levels of DAMPs are associated with disease 
severity (reviewed in Ref. [97]) and serum sRAGE appears to be raised 
[98]. In such contexts, determination of sRAGE levels could be useful for 
risk stratification and potentially, to inform clinical management, e.g., 
to select a course of treatment. In this respect, a clinically relevant 
threshold of sRAGE has so far not been established. Based on our own 
studies in frail older adults, we suggested that values of sRAGE in the 
range of 1600–1800 pg/ml might be relevant to set up a threshold which 
could be used for risk stratification [41,89]. Nevertheless, further 
studies will be required to narrow down and validate this value, for this 
and other clinical conditions. In this respect, future studies should also 
aim to establish if following changes in sRAGE levels over time, could be 
used to ascertain if an individual is responding to a selected course of 
treatment. 
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